[The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease]. Dal-Re R. Rev Neurol 2022;74:207-208.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dal-Re R. [The European Medicines Agency rejects the authorization of aducanumab for Alzheimer's disease]. Rev Neurol 2022;74:207-208.
PMID: 35275397